An exploratory study of treatment sensitivity and prognostic factors in a efficacy and safety study of mFOLFOX6 + bevacizumab versus mFOLFOX6 + panitumumab therapy in patients with chemotherapy-naive unresectable advanced or recurrent colorectal cancer
Phase 3
Completed
- Conditions
- Colorectal cancer
- Registration Number
- JPRN-jRCT1080222785
- Lead Sponsor
- Takeda Pharmaceutical Company Limited
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- completed
- Sex
- All
- Target Recruitment
- 757
Inclusion Criteria
Patients who are enrolled in the main study and personally provided written consent after adequately explained about the contents of the additional study
Exclusion Criteria
Patients who are determined by the investigator or researchers to be not suitable for participating in the additional study
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method exploratory<br>Overall survival (OS)<br>Timeframe: Up to approximately 63 months<br>OS obtained in the main study will be stratified by the presence or absence of mutation of tumor-associated genes in tumor tissues at the baseline of the main study evaluate the relationship between OS and gene mutations. OS will be measured as the time from the date of randomization to the date of death due to any causes.
- Secondary Outcome Measures
Name Time Method